

LabCorp Information Systems 3060 S Church Street Burlington, NC 27215

Specimen Number 183-990-4511-6			Patient I	D	Control Number	Account Number 12311000	Account Phone Number 336-436-8589	Route 50
Patient Last Name BROTHER6 Patient First Name Patient Middle Name					Account Address QA TESTING CENTERXXXXXXXXXXXXXX			
1 adent i list Name			ration whate value		RICH'S TESTINGXXXXXXXXXXXXXXXX			
Patient SS# Pati		Patient Pho	Patient Phone Total Volume		TAPCO BUILDING 2ND FLOORXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX			
Age (Y/M/D)	Date	e of Birth	Sex N	Fasting	BURDINGION NC 2/213-3301			
		Patient Address				Additional Info	rmation	
Date and Time Collected 07/02/07 00:00				nd Time Reported /07 11:22ET	Physician Name	NPI	Physician	ID
TF9T(9) OF	DEBED):		General Co	omments	cose Plasm	2	

Billing Information Required

To enable LabCorp to file an insurance claim on behalf of your patient, please provide or update as indicated the required billing information listed below. The HIPAA Privacy regulation at 45 CFR 164.506 (c) (3) provides that a covered entity (Physician's Office/Referring Provider) may disclose "PHI" to another covered entity (LabCorp) for purposes of payment without patient authorization.

Please provide requested information and return via your service representative or fax to 336-436-0515 within 3 days.

Physician's Signature


Please Provide:

Physician's original signature is required when billing Medicaid, some states allow stamped signatures.

Updated/Corrected	Information:
Physician/Designee	Signature:
	Date:

BROTHER6, 183-990-4511-6 Seq # 0077

Phone: 336-222-7566



Ron Thomason, M.D., Medical Director Brentwood, TN, CLIA I.D. # 44D1066133



Patient Name: TEN PAGE, FAX_1 Ordering Physician: Brian Calabrese, M.D.

Treating Physician: Not Given

Ordering Facility: US LABS DEMO ACCOUNT

Medical Record #: Not Given

Date of Birth,Sex: 10/10/1955, M

Collection Date: 06/04/2008

Received Date: 06/05/2008

Report Date: 06/20/2008

US LABS Ref #: ASP08-002449

Specimen ID #: A

Diagnosis Summary

PART A: L LAT MID: ADENOCARCINOMA PREDICTED GLEASON SCORE 4(2+2) MEASURING mm CORRESPONDING TO 55%

INVOLVEMENT OF THE TOTAL CORE BIOPSY LENGTH.

PART A: L LAT APEX: ADENOCARCINOMA PREDICTED GLEASON SCORE 6(2+4) MEASURING mm CORRESPONDING TO 70%

INVOLVEMENT OF THE TOTAL CORE BIOPSY LENGTH.

PART A: R TRAN ZONE: ADENOCARCINOMA PREDICTED GLEASON SCORE 4(2+2) MEASURING mm CORRESPONDING TO 50%

INVOLVEMENT OF THE TOTAL CORE BIOPSY LENGTH.

PART A: R LAT BASE: BENIGN PROSTATIC GLANDS AND STROMA.


PSA: 25 Gleason Score: 6(2+4) Clinical Stage: T1c


Organ Confined (OC) = 62%

Capsular Penetration (CP) = 33%

Sem. Ves. Involvement (SV+) = 4%

Lymph Node Involvement (LN+) = 2%





(T1c = a non-palpable tumor detected by needle

biopsy.)

This data is extracted from the 2001 AUA abstract #952: Contemporary Update of Prostate Cancer Staging Nomograms (Partin Tables). Partin, Walsh, Epstein, Pearson. The statistical analysis of this data has not been determined or evaluated by US LABS.

Revision Reason:

This report was in order to change the comments.

Electronically Signed by pathology1 User, M.D. Ph.D. on 6/20/2008 at US LABS

pathology1 User, M.D. Ph.D. Medical Director

Disclaimer

This Test was performed at 2601 Campus Drive, Irvine, CA, 92612

Any image(s) that accompany this report is/are a representative image(s) only and should not be used to render a diagnosis.

US LABS DEMO ACCOUNT | 2601 Campus Drive | Irvine, CA 92614

Page 2 of 2



US LABS | Client Services: 800-710-1800 | www.uslabs.net